Seeking Alpha

Pharmasset (VRUS) drops 3.6% after announcing it will "discontinue all treatment" in ongoing...

Pharmasset (VRUS) drops 3.6% after announcing it will "discontinue all treatment" in ongoing Phase 2b trials that involves use of its PSI-938 hepatitis drug. The company says it "detected laboratory abnormalities associated with liver function" in patients using PSI-938.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|